Evidence map›Paper›PMID 41034591›Full record

SynthesisNeuroradiology2025

LVIS versus enterprise stents for stent-assisted coiling of intracranial aneurysms: a systematic review and meta-analysis.

Lucca Tamara Alves Carretta, Ocilio Ribeiro Gonçalves, Mariana Lee Han, Kenzo Ogasawara Donato, Yasmin Picanço Silva, Luciano Falcão, Rian Barreto Arrais Rodrigues de Morais, Nicole Baptista de Oliveira, Mariana Letícia de Bastos Maximiano, Ahmet Günkan

Abstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Publisher
In one paragraph

Synthesis in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lucca Tamara Alves CarrettaDepartment of Medicine, Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Vitória, Brazil. luccatamara12@gmail.com.
Ocilio Ribeiro GonçalvesDepartment of Medicine, Federal University of Piauí, Teresina, Brazil.
Mariana Lee HanDepartment of Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Kenzo Ogasawara DonatoDepartment of Medicine, Bahiana School of Medicine and Public Health, Salvador, Brazil.
Yasmin Picanço SilvaHealthcare Institution of South Iceland, Selfoss, Iceland.
Luciano FalcãoDepartment of Medicine, Bahiana School of Medicine and Public Health, Salvador, Brazil.
Rian Barreto Arrais Rodrigues de MoraisDepartment of Medicine, Centro Universitário São Lucas, Porto Velho, Brazil.
Nicole Baptista de OliveiraDepartment of Medicine, Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Vitória, Brazil. nicole.trabalho23@gmail.com.
Mariana Letícia de Bastos MaximianoFluminense Federal University, Niterói, Brazil.
Ahmet GünkanDivision of Vascular and Interventional Radiology, Department of Radiology, University of Arizona, Tucson, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis systematic review and meta-analysis aimed to compare the clinical and angiographic outcomes of the LVIS versus the Enterprise stent for the treatment of intracranial aneurysms (IAs).

methodsEligible studies were extracted from PubMed, Scopus, and Embase comparing LVIS/Enterprise. Data on angiographic occlusion rates, neurological deficits, in-stent stenosis, hemorrhagic complications, thromboembolic complications and aneurysm recanalization were analyzed with statistical methods.

results5 observational studies (912 patients: 457 treated with LVIS and 455 with Enterprise) were analyzed. LVIS was linked to a significantly lower likelihood of Raymond-Roy Occlusion Classification (RROC) Class 3 (RR 0.30; 95% CI 0.13-0.71; I²=0%) and aneurysm recanalization (RR 0.38; 95% CI 0.18-0.82; I²=0%). No statistically significant differences were found between the two groups regarding mRS 0-2, RROC Class 1 or 2, or the incidence of neurological deficits, in-stent stenosis, hemorrhagic or thromboembolic events.

conclusionLVIS and Enterprise demonstrate safety and efficacy in the endovascular management of IAs. LVIS may provide improved angiographic outcomes by lowering the risk of recurrence and incomplete occlusion. These findings support its potential advantage in treating complex aneurysms. Further confirmation through randomized controlled trials (RCT) is needed.

Indexed as

Embolization, TherapeuticEndovascular ProceduresIntracranial AneurysmStentsCerebral AngiographyHumansTreatment OutcomeEndovascular treatmentEnterprise stentIntracranial aneurysmLVIS stentMeta-AnalysisSystematic review

Identifiers

PMID41034591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.